·Week of September 21-25, 2026

Clinical Trials Brief | September 28, 2026

This week: the Ervebo trial against Bundibugyo Ebola starting in Ituri, FDA commissioner nominee Heidi Overton backing advisory committees and career-staff product decisions at her hearing, EMA piloting a new pre-submission model for marketing applications, FDA replacing 'animal tests' with 'nonclinical tests' across its drug regulations, and the draft biosimilar user fee deal proposing a provisional approval pathway.

The Ervebo trial against Bundibugyo Ebola starts in Ituri, targeting 20,000 frontline workers over nine to twelve months

What changed

On Saturday, September 19, 2026, the first frontline volunteers in Bunia, the capital of Ituri province and epicentre of the outbreak, were vaccinated with Ervebo as part of a clinical trial, AFP reported. They included doctors, nurses and disinfection staff. The study aims to vaccinate about 20,000 frontline workers in Ituri and North Kivu over nine to twelve months and follow them to assess whether Ervebo, licensed against Zaire ebolavirus, protects against Bundibugyo. Bernama reported that a separate Phase 3 trial using randomised ring vaccination is also planned to assess effectiveness more rigorously. By September 17, 3,771 people had been vaccinated in Tshopo and Bas-Uélé provinces, and the DRC government reported 7,541 confirmed cases and 3,639 deaths, a case fatality rate of 48.3%. DRC response lead Professor Steve Ahuka told reporters that the vaccine's level of efficacy against Bundibugyo is unknown.

Why it matters

This completes the shift described in this brief's September 14 issue: frontline vaccination is now organised as research, as WHO recommended. Two designs will run in parallel: a large observational cohort of vaccinated health workers, and a randomised ring-vaccination trial for a more rigorous efficacy estimate. That combination maximises access while preserving the possibility of a clean answer, but the two datasets will need careful separation in analysis. The outbreak has continued to grow since the PHEIC declaration in May.

Takeaway

When an observational cohort and a randomised trial run in the same population, define upfront how participants move between them, how vaccination status is recorded across both, and which dataset will be used for which regulatory question. The ring-vaccination trial's start date is the next milestone to watch.

Sources

This item is grounded in AFP reporting via DH Net (September 19, 2026) and Bernama (September 20, 2026).

At her confirmation hearing, FDA nominee Heidi Overton backs advisory committees and career-staff product decisions

What changed

On September 24, 2026, Heidi Overton appeared before the Senate Health, Education, Labor and Pensions (HELP) Committee for her confirmation hearing as FDA commissioner. According to The FDA Group, she said in her opening remarks that, if confirmed, she would work with career professionals to make sure every aspect of clinical trials and drug development is optimised. She said she would take the recommendations of career staff on product determinations and called advisory committee meetings a critical part of FDA's processes. Fierce Biotech reported that her opening statement focused on speeding up drug development to compete with China. Senators from both parties questioned her on vaccines, mifepristone, flavored e-cigarette rules and political independence. According to Healio and Fierce, she said FDA-approved vaccines have met the standards for safety and efficacy, and AP reported that she declined to prejudge FDA's ongoing review of mifepristone. HELP Chair Bill Cassidy pressed her on independence from the White House. Holland & Knight reported a committee vote scheduled for September 30.

Why it matters

For clinical research, the most relevant commitments are procedural: deferring to career staff on product decisions and treating advisory committees as essential. This summer saw several decisions where FDA leadership departed from review-team recommendations, as with RP1. Overton's stated priority on clinical trial speed is consistent with Operation TrialBlazer and the Expedited IND pilot, which suggests continuity on trial policy if she is confirmed. Her confirmation is not yet assured.

Takeaway

Sponsors should not assume a policy reset on trial acceleration under a new commissioner. The stated commitments on career staff and advisory committees, if they hold, would make review outcomes somewhat more predictable. Watch the committee vote and any floor vote.

EMA pilots a new pre-submission model for marketing applications planned for February 2027 to September 2028

What changed

In September 2026, EMA launched an 18-month voluntary pilot testing a revised model for pre-submission interactions (PSI) ahead of initial marketing authorisation applications. According to EMA, the pilot introduces shared ownership and early dialogue between applicants, rapporteurs and EMA on submission timing, and includes a revised written PSI form and a joint pre-submission meeting called EUSTART. It is open to applicants planning to submit an initial marketing authorisation application between February 2027 and September 2028. EMA has published guidance describing the full process and expectations for applicants, rapporteurs and EMA.

Why it matters

Late or poorly planned submissions are a recurring cause of avoidable clock stops and extended reviews in the centralised procedure. Bringing rapporteurs into submission planning earlier is meant to reduce surprises, and it fits the wider EU effort under the new pharmaceutical legislation to make assessments faster and more predictable. For clinical teams, earlier dialogue means questions about pivotal trial design, data cut-offs and pending analyses may be raised before the dossier is locked.

Takeaway

Sponsors with EU filings planned for 2027-2028 should consider joining the pilot, and should make sure clinical leads, not only regulatory affairs, are prepared to discuss pivotal data timing and open analyses in the pre-submission meeting.

Sources

This item is grounded in EMA's pre-submission interactions model pilot page. EMA states the pilot launched in September 2026; I could not confirm the exact day.

FDA replaces 'animal tests' with 'nonclinical tests' across its drug regulations, opening the door wider to non-animal safety evidence

What changed

On September 21, 2026, FDA issued a direct final rule replacing references to animal testing with the term "nonclinical tests" in nearly 40 places in its drug and biologics regulations. According to The FDA Group, the rule implements changes Congress made in late 2022 that define nonclinical tests to include in vitro, in silico, in chemico and non-human in vivo methods. The changes take effect February 4, and FDA also published a companion proposed rule, with comments due December 7, in case it receives significant adverse comment. PharmTech notes that the rule does not remove animal studies or change safety standards; it clarifies that methods such as human cell cultures, organ-on-chip systems and computer models can support pre-human safety assessment. FDA also launched a database of 25 case examples of new approach methodologies drawn from its review materials. Acting Commissioner Kyle Diamantas said the goal is not to replace one rigid approach with another.

Why it matters

This is a safety item in the sense that it changes how the first-in-human safety case can be built. Non-animal methods can be more predictive for some human-specific toxicities, but they also bring new validation questions: context of use, human biological relevance, technical characterisation and fit-for-purpose assessment, as PharmTech summarises. The database of real review examples matters most in practice, because it shows sponsors what FDA has already accepted.

Takeaway

Nonclinical and early clinical teams should review the NAM case database before planning IND-enabling packages, and document the context of use and validation for any non-animal method used to support starting dose or safety margins. Investigator brochures should describe clearly which safety conclusions rest on non-animal evidence.

The draft biosimilar user fee deal proposes a provisional approval pathway, a week after PDUFA VIII proposed rewarding US Phase 1 trials

What changed

On September 24, 2026, FDA released the draft commitment letter for the next Biosimilar User Fee Act and scheduled an October 26 public meeting. If Congress reauthorises it, the programme would take effect October 1, 2027. According to The FDA Group, proposed changes include new supplement categories with four- and six-month review timelines, a provisional approval process similar to the one for generic drugs, a review extension allowing FDA to address resolvable issues late in review that might otherwise lead to a complete response letter, a risk-based lifecycle approach to manufacturing facility deficiencies, and new meetings to resolve facility-related approvability issues. A week earlier, at a September 16 public meeting on the draft PDUFA VIII commitment letter, Deputy Commissioner Grace Graham highlighted a proposed cut in application fees for companies that anchor Phase 1 trials in the US.

Why it matters

User fee agreements set FDA's operating rules for five years at a time, so these drafts matter more than most guidance documents. Two themes stand out. Both drafts treat CMC and facility issues as a major source of delay to be designed out, consistent with this year's examples of approvals held up by manufacturing sites. And the PDUFA proposal turns trial location into a fee incentive, the most direct financial lever yet in the broader effort to bring early-phase trials back to the US.

Takeaway

Sponsors and trade associations should prepare comments before the October 26 BsUFA meeting and track the PDUFA VIII recommendations FDA must deliver to Congress by January 2027. If the Phase 1 fee incentive survives, it will become a real factor in where companies place first-in-human studies.

Sources

This item is grounded in FDA's draft BsUFA commitment letter of September 24, 2026 and the PDUFA VIII public meeting of September 16, 2026, as summarised by The FDA Group.

Clinical Trials Brief is an educational commentary archive, not a real-time news service. Confirmed facts are based on publicly cited sources where possible. Analytical comments, comparisons, and forward-looking views are personal interpretation unless otherwise stated.